-$0.35 EPS Expected for Tilray Inc (NASDAQ:TLRY) This Quarter
Wall Street analysts expect Tilray Inc (NASDAQ:TLRY) to post earnings of ($0.35) per share for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Tilray’s earnings, with estimates ranging from ($0.46) to ($0.25). Tilray posted earnings per share of ($0.29) during the same quarter last year, which indicates a negative year over year growth rate of 20.7%. The firm is scheduled to issue its next earnings results on Monday, March 16th.
On average, analysts expect that Tilray will report full-year earnings of ($1.39) per share for the current year, with EPS estimates ranging from ($1.44) to ($1.29). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.56) to ($0.60). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Tilray.
Tilray (NASDAQ:TLRY) last issued its earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.05). The company had revenue of $51.10 million for the quarter, compared to analysts’ expectations of $49.57 million. Tilray had a negative return on equity of 40.30% and a negative net margin of 97.39%. The business’s revenue was up 411.0% compared to the same quarter last year. During the same period last year, the business posted ($0.08) earnings per share.
TLRY traded up $0.54 during trading on Friday, hitting $20.97. The stock had a trading volume of 6,102,476 shares, compared to its average volume of 3,931,995. The company has a market capitalization of $2.05 billion, a PE ratio of -15.31 and a beta of 3.87. Tilray has a twelve month low of $15.01 and a twelve month high of $89.88. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.69 and a current ratio of 2.54. The stock has a 50 day simple moving average of $17.69 and a two-hundred day simple moving average of $27.64.
In other Tilray news, CEO Brendan Kennedy sold 100,000 shares of Tilray stock in a transaction on Monday, January 13th. The shares were sold at an average price of $16.40, for a total value of $1,640,000.00. Following the completion of the transaction, the chief executive officer now owns 4,666,740 shares of the company’s stock, valued at $76,534,536. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael Auerbach sold 31,875 shares of Tilray stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $19.05, for a total transaction of $607,218.75. Following the completion of the transaction, the director now directly owns 31,875 shares of the company’s stock, valued at approximately $607,218.75. The disclosure for this sale can be found here. Insiders sold 231,875 shares of company stock valued at $4,077,219 in the last ninety days. 3.40% of the stock is owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in TLRY. Wealthcare Advisory Partners LLC increased its stake in shares of Tilray by 100.8% during the third quarter. Wealthcare Advisory Partners LLC now owns 996 shares of the company’s stock worth $25,000 after purchasing an additional 500 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Tilray during the second quarter worth about $46,000. AdvisorNet Financial Inc purchased a new stake in shares of Tilray during the third quarter worth about $58,000. Wells Fargo & Company MN increased its stake in shares of Tilray by 1,535.0% during the second quarter. Wells Fargo & Company MN now owns 1,635 shares of the company’s stock worth $76,000 after purchasing an additional 1,535 shares in the last quarter. Finally, Penserra Capital Management LLC purchased a new stake in shares of Tilray during the third quarter worth about $121,000. 8.61% of the stock is owned by institutional investors and hedge funds.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Featured Article: Is it Safe to Invest in Commodities?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.